Navigation Links
Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials
Date:1/4/2012

PHOENIX, Jan. 4, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug. The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development of the KDM-1102 drug is now completed and can be produce in large volume.

"We are pleased with the progress we have been making in our development program on KDM-1102, our Second lead therapeutic drug for cardiovascular and anxiety attacks," said Dr. Hassan Salari, Kedem Pharmaceuticals, President & CEO.

About Sublingual Technology

The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology may apply to over 40 major drugs which all can benefit from this route.

About Kedem Pharmaceuticals Inc. (KDMP.ob) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for anxiety attack, osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.

About Corealis Pharma Inc. is a private Montreal based contractual formulation development and clinical supply manufacturing company of pharmaceutical oral solid dosage forms for United-States, European, and Canadian trials (www.corealispharma.com).

Forward-looking Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform  Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to unforeseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities. 

For further information, contact:
Kedem Investor Relations 1 866 465-6551
info@kedempharmaceuticals.com

Or

Kelly Black
Premier Media Services 1 480 649 8224
kblack@premiermediaservice.com

 


'/>"/>
SOURCE Kedem Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merz Pharmaceuticals Receives J-Code For Xeomin® (incobotulinumtoxinA)
2. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
3. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
4. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Jazz Pharmaceuticals to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Transaction
7. Radient Pharmaceuticals Announces Reverse Stock Split
8. Idenix Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Endo Pharmaceuticals to Present at J.P. Morgan 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Physician General Dr. ... and Alcohol Programs Jennifer Smith commended South ... training for and using naloxone, a life-saving overdose reversal ... , a recovery specialist and overdose survivor who was ... providers. "A significant part of fighting the ...
(Date:2/24/2017)... , Feb. 23, 2017 The U.S. ... the PhenoTest BC Kit, performed on the Pheno ... organisms that cause bloodstream infections and provide information ... respond to (antibiotic sensitivity). The test also reduces ... this important information, which can guide antibiotic treatment ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no ... which often leads to a host of health issues, including urinary incontinence. However, ... Society discovered that good overall muscle strength in older women, particularly in ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... for Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring ... mind and body, these individual customized retreats offer the winter-weary soul an excellent ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical ... to studying to become a nun. Now, she writes about God, when she isn’t swimming ... Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look at ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media center that ... songs, movies, TV shows and much more apps for user exploration. Its innovative acoustic ... view of 1280 x 720 provides crisp images with remarkable clarity and color. The ...
(Date:2/27/2017)... ... 2017 , ... Sunshine Coast Health Centre (SCHC), one of ... https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered massage ... commitment to innovation in drug rehab and alcohol treatment strategies beyond a "punishment" ...
Breaking Medicine News(10 mins):